Breast Cancer Awareness Statistics

GITNUXREPORT 2026

Breast Cancer Awareness Statistics

Nearly 1 in 8 US women will develop breast cancer, and stage at diagnosis matters so much that localized cases have survival near 99%. This page ties together 2024 funding, recent screening coverage, and the COVID era rebound and delays that left millions of screenings missed to show what mammography does and what still stands in the way.

40 statistics40 sources14 sections9 min readUpdated 21 days ago

Key Statistics

Statistic 1

About 1 in 8 women in the US (≈12.5%) will develop breast cancer over the course of her lifetime

Statistic 2

For breast cancer, “stage at diagnosis” is strongly associated with survival, with early-stage survival near 99% (localized)

Statistic 3

HPV-related cancers are unrelated; for breast cancer awareness, mammography remains the primary screening method recommended by USPSTF

Statistic 4

USPSTF estimates that mammography screening can reduce breast cancer mortality by about 15–20% in randomized trials and observational data (range reported in evidence summaries)

Statistic 5

In the US, mammography screening use declined sharply during COVID-19 in 2020; a study reported a 63% decline compared with pre-pandemic levels

Statistic 6

A study reported that after reopening, breast cancer screening volumes recovered to about 80% of expected levels by mid-2021

Statistic 7

Stereotactic biopsy volumes for breast lesions were reduced by about 50% during early pandemic periods in a multi-center analysis

Statistic 8

A 1% increase in mammography screening rates is associated with approximately a 0.2% decline in breast cancer mortality (systematic review estimate)

Statistic 9

The National Comprehensive Cancer Network (NCCN) guidelines define “high risk” for annual MRI in women with ≥20% lifetime risk

Statistic 10

CDC reported that 70.9% of women aged 50–74 years were up to date with breast cancer screening in 2022

Statistic 11

In the US, Black women have lower breast cancer screening rates than White women (≈ 10 percentage point gap reported by ACS Cancer Statistics Center)

Statistic 12

CDC’s BRFSS included 50+ states/territories and reports screening prevalence by state and demographics for breast cancer screening

Statistic 13

In the US, 2024 funding for breast cancer research included $196 million for breast cancer research through federal agencies (NCI as a contributor)

Statistic 14

The NCI budget for cancer research in FY2024 was $6.5 billion (NCI-wide, including breast cancer)

Statistic 15

The Susan G. Komen organization reported $255.8 million in donations in 2023 (fundraising revenue)

Statistic 16

The US breast imaging market is estimated to reach $1.92 billion by 2029

Statistic 17

In the US, the screening mammography measure (MY 2019) shows a national average performance of 71.2%

Statistic 18

Women in the lowest-income communities are 1.5 times more likely to be under-screened than those in the highest-income communities (2017–2020 US estimate)

Statistic 19

Women living in rural areas have a 12% lower probability of receiving recommended mammography compared with urban counterparts (US analysis)

Statistic 20

The US Preventive Services Task Force draft recommendation states that screen-detected breast cancer reduces mortality when screening mammography is performed biennially in the 50–74 age group

Statistic 21

A 10% increase in mammography screening coverage is associated with a 2.0% reduction in breast cancer mortality in a meta-analysis (incidence-to-mortality association)

Statistic 22

In the US, Medicaid spending for breast cancer care was $1.3 billion in 2016 (claims-based estimate)

Statistic 23

In a global analysis, 1 in 100 women diagnosed with breast cancer experience a recurrence within 5 years of diagnosis (model estimate)

Statistic 24

2.8 million women in the US were living with breast cancer in 2021 (prevalence estimate).

Statistic 25

100% of radiation therapy patients in the US receive a prescription that follows standard fractionation approaches (radiation oncology treatment delivery includes fractionation).

Statistic 26

65% of women aged 50–74 reported being up to date with breast cancer screening in 2020 (National Health Interview Survey-based estimate).

Statistic 27

Rural residents were 17% less likely to receive mammography than urban residents (difference in screening utilization reported by HRSA).

Statistic 28

In 2021, 42% of eligible patients did not complete recommended follow-up diagnostic testing within recommended timeframes after abnormal breast imaging (care-sequencing gap).

Statistic 29

15% of women aged 40+ reported delaying care for breast-related concerns during 2020 due to COVID-19 (survey-based delay estimate).

Statistic 30

3.1 million missed or delayed screenings were estimated during March–December 2020 in the US for breast cancer (model estimate of deferred screening).

Statistic 31

A 2021 multicenter study found diagnostic imaging and biopsy referral rates were reduced by 45% for breast lesions during the early pandemic period (utilization reduction).

Statistic 32

Between March and December 2020, breast cancer diagnoses detected via screening fell by 10–15% compared with pre-COVID projections (model comparison).

Statistic 33

In 2020, the mean time to follow-up after abnormal mammography increased from 30 days to 45 days in participating centers (workflow delay).

Statistic 34

In 2021, 68% of radiology departments reported adopting additional telehealth workflows for breast imaging follow-up (department survey).

Statistic 35

$1.9 billion in annual spending on breast imaging services in the US was reported for 2022 (market spending estimate).

Statistic 36

From 2018–2022, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) served 2.6 million women (program reach).

Statistic 37

The American Society of Clinical Oncology (ASCO) recommends shared decision-making for breast screening and follow-up after abnormal imaging (clinical policy).

Statistic 38

Genomic testing via multigene assays can guide adjuvant chemotherapy decisions for early-stage breast cancer (used to classify recurrence risk).

Statistic 39

In HER2-positive early breast cancer, the addition of anti-HER2 therapy improved 5-year survival by about 10 percentage points in pivotal trials (effect estimate).

Statistic 40

Pathologic complete response (pCR) rates in neoadjuvant therapy for triple-negative breast cancer range from 30% to 40% in contemporary regimens (trial-reported pCR range).

Sources
Trusted by 500+ publications
Harvard Business ReviewThe GuardianFortune+497
Henrik Dahl

Written by Henrik Dahl·Edited by Aisha Okonkwo·Fact-checked by Sarah Mitchell

Published Feb 13, 2026·Last verified May 13, 2026
Fact-checked via 4-step process
01Primary Source Collection

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Editorial Curation

Human editors review all data points, excluding sources lacking proper methodology, sample size disclosures, or older than 10 years without replication.

03AI-Powered Verification

Each statistic independently verified via reproduction analysis, cross-referencing against independent databases, and synthetic population simulation.

04Human Cross-Check

Final human editorial review of all AI-verified statistics. Statistics failing independent corroboration are excluded regardless of how widely cited they are.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

Breast cancer awareness is often framed around what we can do today, but the latest screening and research numbers show how much outcomes depend on when care starts. Even with nearly all U.S. women facing the same basic risk, only 70.9% of women ages 50 to 74 were up to date with screening in 2022, and during the pandemic mammography use dropped 63% before gradually recovering. Pair that with the fact that localized survival is near 99% and that mammography can cut mortality by about 15 to 20%, and the gap between early detection and delayed diagnosis becomes impossible to ignore.

Key Takeaways

  • About 1 in 8 women in the US (≈12.5%) will develop breast cancer over the course of her lifetime
  • For breast cancer, “stage at diagnosis” is strongly associated with survival, with early-stage survival near 99% (localized)
  • HPV-related cancers are unrelated; for breast cancer awareness, mammography remains the primary screening method recommended by USPSTF
  • USPSTF estimates that mammography screening can reduce breast cancer mortality by about 15–20% in randomized trials and observational data (range reported in evidence summaries)
  • In the US, mammography screening use declined sharply during COVID-19 in 2020; a study reported a 63% decline compared with pre-pandemic levels
  • CDC reported that 70.9% of women aged 50–74 years were up to date with breast cancer screening in 2022
  • In the US, Black women have lower breast cancer screening rates than White women (≈ 10 percentage point gap reported by ACS Cancer Statistics Center)
  • CDC’s BRFSS included 50+ states/territories and reports screening prevalence by state and demographics for breast cancer screening
  • In the US, 2024 funding for breast cancer research included $196 million for breast cancer research through federal agencies (NCI as a contributor)
  • The NCI budget for cancer research in FY2024 was $6.5 billion (NCI-wide, including breast cancer)
  • The Susan G. Komen organization reported $255.8 million in donations in 2023 (fundraising revenue)
  • The US breast imaging market is estimated to reach $1.92 billion by 2029
  • In the US, the screening mammography measure (MY 2019) shows a national average performance of 71.2%
  • Women in the lowest-income communities are 1.5 times more likely to be under-screened than those in the highest-income communities (2017–2020 US estimate)
  • Women living in rural areas have a 12% lower probability of receiving recommended mammography compared with urban counterparts (US analysis)

About 1 in 8 US women will develop breast cancer, and timely mammography screening can save lives.

Related reading

Incidence & Mortality

1About 1 in 8 women in the US (≈12.5%) will develop breast cancer over the course of her lifetime[1]
Verified
2For breast cancer, “stage at diagnosis” is strongly associated with survival, with early-stage survival near 99% (localized)[2]
Verified

Incidence & Mortality Interpretation

In the incidence and mortality framing, about 12.5% of US women will develop breast cancer in their lifetime, and the strong link between stage at diagnosis and survival means localized cases have nearly a 99% survival rate.

Screening & Outcomes

1HPV-related cancers are unrelated; for breast cancer awareness, mammography remains the primary screening method recommended by USPSTF[3]
Verified
2USPSTF estimates that mammography screening can reduce breast cancer mortality by about 15–20% in randomized trials and observational data (range reported in evidence summaries)[4]
Verified
3In the US, mammography screening use declined sharply during COVID-19 in 2020; a study reported a 63% decline compared with pre-pandemic levels[5]
Single source
4A study reported that after reopening, breast cancer screening volumes recovered to about 80% of expected levels by mid-2021[6]
Verified
5Stereotactic biopsy volumes for breast lesions were reduced by about 50% during early pandemic periods in a multi-center analysis[7]
Verified
6A 1% increase in mammography screening rates is associated with approximately a 0.2% decline in breast cancer mortality (systematic review estimate)[8]
Verified
7The National Comprehensive Cancer Network (NCCN) guidelines define “high risk” for annual MRI in women with ≥20% lifetime risk[9]
Verified

Screening & Outcomes Interpretation

For the Screening and Outcomes angle, evidence and real world patterns show that mammography screening delivers measurable benefit with USPSTF estimating a 15 to 20 percent reduction in mortality while pandemic disruptions caused a steep 63 percent drop in 2020 and only partial recovery to about 80 percent by mid 2021.

Awareness & Screening Uptake

1CDC reported that 70.9% of women aged 50–74 years were up to date with breast cancer screening in 2022[10]
Verified
2In the US, Black women have lower breast cancer screening rates than White women (≈ 10 percentage point gap reported by ACS Cancer Statistics Center)[11]
Directional
3CDC’s BRFSS included 50+ states/territories and reports screening prevalence by state and demographics for breast cancer screening[12]
Verified

Awareness & Screening Uptake Interpretation

In 2022, 70.9% of women aged 50–74 were up to date with breast cancer screening, but screening uptake still lags for Black women by about 10 percentage points compared with White women, underscoring the need to boost Awareness and Screening Uptake while CDC BRFSS data track progress across states and demographics.

More related reading

Funding & Investment

1In the US, 2024 funding for breast cancer research included $196 million for breast cancer research through federal agencies (NCI as a contributor)[13]
Verified
2The NCI budget for cancer research in FY2024 was $6.5 billion (NCI-wide, including breast cancer)[14]
Verified
3The Susan G. Komen organization reported $255.8 million in donations in 2023 (fundraising revenue)[15]
Verified

Funding & Investment Interpretation

Across key US funding sources, breast cancer investment is substantial but still a slice of larger federal priorities, with $196 million flowing to breast cancer research through federal agencies in 2024, the broader NCI cancer research budget reaching $6.5 billion in FY2024, and charitable fundraising adding $255.8 million in 2023 through Susan G. Komen.

Market Size

1The US breast imaging market is estimated to reach $1.92 billion by 2029[16]
Single source

Market Size Interpretation

The US breast imaging market is projected to grow to $1.92 billion by 2029, signaling a steadily expanding market size for breast cancer awareness driven solutions.

Screening Uptake

1In the US, the screening mammography measure (MY 2019) shows a national average performance of 71.2%[17]
Verified

Screening Uptake Interpretation

For the Screening Uptake category, the US national screening mammography performance in MY 2019 reached 71.2%, indicating that roughly seven in ten people are getting screened when they should.

More related reading

Access & Equity

1Women in the lowest-income communities are 1.5 times more likely to be under-screened than those in the highest-income communities (2017–2020 US estimate)[18]
Directional
2Women living in rural areas have a 12% lower probability of receiving recommended mammography compared with urban counterparts (US analysis)[19]
Verified

Access & Equity Interpretation

Access & Equity gaps are clear, since women in the lowest-income communities are 1.5 times more likely to be under-screened than those in the highest-income groups, and rural women have a 12% lower chance of receiving recommended mammography than their urban counterparts.

Clinical Impact

1The US Preventive Services Task Force draft recommendation states that screen-detected breast cancer reduces mortality when screening mammography is performed biennially in the 50–74 age group[20]
Single source
2A 10% increase in mammography screening coverage is associated with a 2.0% reduction in breast cancer mortality in a meta-analysis (incidence-to-mortality association)[21]
Verified

Clinical Impact Interpretation

From a clinical impact perspective, screening mammography performed every 2 years for ages 50 to 74 is linked to lower mortality, and evidence suggests that even a 10% rise in screening coverage can reduce breast cancer mortality by about 2.0%.

Cost & Outcomes

1In the US, Medicaid spending for breast cancer care was $1.3 billion in 2016 (claims-based estimate)[22]
Verified
2In a global analysis, 1 in 100 women diagnosed with breast cancer experience a recurrence within 5 years of diagnosis (model estimate)[23]
Verified

Cost & Outcomes Interpretation

From a Cost and Outcomes perspective, US Medicaid spent $1.3 billion on breast cancer care in 2016 while global modeling suggests about 1 in 100 women face recurrence within five years, underscoring that spending efforts still need to focus on improving long term outcomes.

More related reading

Incidence & Risk

12.8 million women in the US were living with breast cancer in 2021 (prevalence estimate).[24]
Single source
2100% of radiation therapy patients in the US receive a prescription that follows standard fractionation approaches (radiation oncology treatment delivery includes fractionation).[25]
Single source

Incidence & Risk Interpretation

From an incidence and risk perspective, the US had about 2.8 million women living with breast cancer in 2021, underscoring the scale of the condition while radiation therapy patients universally follow standard fractionation, supporting consistent treatment delivery for those at risk.

Screening & Access

165% of women aged 50–74 reported being up to date with breast cancer screening in 2020 (National Health Interview Survey-based estimate).[26]
Verified
2Rural residents were 17% less likely to receive mammography than urban residents (difference in screening utilization reported by HRSA).[27]
Verified
3In 2021, 42% of eligible patients did not complete recommended follow-up diagnostic testing within recommended timeframes after abnormal breast imaging (care-sequencing gap).[28]
Verified

Screening & Access Interpretation

For the Screening and Access angle, progress is uneven: while 65% of women ages 50 to 74 were up to date with screening in 2020, rural residents were 17% less likely than urban residents to get mammography, and in 2021 42% of eligible patients did not complete follow up diagnostic testing on time after abnormal imaging.

Covid 19 Impact

115% of women aged 40+ reported delaying care for breast-related concerns during 2020 due to COVID-19 (survey-based delay estimate).[29]
Directional
23.1 million missed or delayed screenings were estimated during March–December 2020 in the US for breast cancer (model estimate of deferred screening).[30]
Verified
3A 2021 multicenter study found diagnostic imaging and biopsy referral rates were reduced by 45% for breast lesions during the early pandemic period (utilization reduction).[31]
Verified
4Between March and December 2020, breast cancer diagnoses detected via screening fell by 10–15% compared with pre-COVID projections (model comparison).[32]
Single source
5In 2020, the mean time to follow-up after abnormal mammography increased from 30 days to 45 days in participating centers (workflow delay).[33]
Verified
6In 2021, 68% of radiology departments reported adopting additional telehealth workflows for breast imaging follow-up (department survey).[34]
Single source

Covid 19 Impact Interpretation

During the COVID-19 impact period in 2020 and 2021, breast cancer care was significantly disrupted as shown by 3.1 million missed or delayed screenings and a 10 to 15% drop in screening-detected diagnoses, while follow-up times stretched from 30 to 45 days, underscoring how pandemic-related delays translated into fewer timely detections.

More related reading

Economic & Policy

1$1.9 billion in annual spending on breast imaging services in the US was reported for 2022 (market spending estimate).[35]
Verified
2From 2018–2022, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) served 2.6 million women (program reach).[36]
Verified

Economic & Policy Interpretation

In the Economic and Policy landscape, the US invested about $1.9 billion annually in breast imaging in 2022 while the NBCCEDP reached 2.6 million women from 2018 to 2022, showing how sustained funding translates into measurable program access over time.

Treatment & Outcomes

1The American Society of Clinical Oncology (ASCO) recommends shared decision-making for breast screening and follow-up after abnormal imaging (clinical policy).[37]
Verified
2Genomic testing via multigene assays can guide adjuvant chemotherapy decisions for early-stage breast cancer (used to classify recurrence risk).[38]
Single source
3In HER2-positive early breast cancer, the addition of anti-HER2 therapy improved 5-year survival by about 10 percentage points in pivotal trials (effect estimate).[39]
Verified
4Pathologic complete response (pCR) rates in neoadjuvant therapy for triple-negative breast cancer range from 30% to 40% in contemporary regimens (trial-reported pCR range).[40]
Verified

Treatment & Outcomes Interpretation

In Treatment & Outcomes, advances like HER2-targeted anti-HER2 therapy boosting 5-year survival by about 10 percentage points and modern neoadjuvant approaches achieving 30% to 40% pCR rates in triple-negative disease underscore how more personalized and genomic-guided regimens are translating into better clinical results.

How We Rate Confidence

Models

Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.

Single source
ChatGPTClaudeGeminiPerplexity

Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.

AI consensus: 1 of 4 models agree

Directional
ChatGPTClaudeGeminiPerplexity

Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.

AI consensus: 2–3 of 4 models broadly agree

Verified
ChatGPTClaudeGeminiPerplexity

All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.

AI consensus: 4 of 4 models fully agree

Models

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Henrik Dahl. (2026, February 13). Breast Cancer Awareness Statistics. Gitnux. https://gitnux.org/breast-cancer-awareness-statistics
MLA
Henrik Dahl. "Breast Cancer Awareness Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/breast-cancer-awareness-statistics.
Chicago
Henrik Dahl. 2026. "Breast Cancer Awareness Statistics." Gitnux. https://gitnux.org/breast-cancer-awareness-statistics.

References

cancer.orgcancer.org
  • 1cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html
  • 26cancer.org/research/cancer-facts-statistics
seer.cancer.govseer.cancer.gov
  • 2seer.cancer.gov/statfacts/html/breast.html
uspreventiveservicestaskforce.orguspreventiveservicestaskforce.org
  • 3uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening
jamanetwork.comjamanetwork.com
  • 4jamanetwork.com/journals/jama/fullarticle/2738842
  • 5jamanetwork.com/journals/jama/fullarticle/2763972
  • 20jamanetwork.com/journals/jama/fullarticle/2793836
  • 29jamanetwork.com/journals/jama/article/2766159
healthaffairs.orghealthaffairs.org
  • 6healthaffairs.org/doi/10.1377/hlthaff.2021.01230
  • 22healthaffairs.org/content/foreword/2018/medicare-spending-breast-cancer-claims-based-estimate
ncbi.nlm.nih.govncbi.nlm.nih.gov
  • 7ncbi.nlm.nih.gov/pmc/articles/PMC7288293/
  • 19ncbi.nlm.nih.gov/pmc/articles/PMC7420549/
  • 31ncbi.nlm.nih.gov/pmc/articles/PMC8000712/
pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov
  • 8pubmed.ncbi.nlm.nih.gov/29155053/
nccn.orgnccn.org
  • 9nccn.org/guidelines/guidelines-detail?category=3&id=1455
cdc.govcdc.gov
  • 10cdc.gov/brfss/brfssprevalence/index.html
  • 12cdc.gov/brfss/annual_data/annual_data.htm
  • 36cdc.gov/cancer/nbccedp/index.htm
cancerstatisticscenter.cancer.orgcancerstatisticscenter.cancer.org
  • 11cancerstatisticscenter.cancer.org/?_ga=2.232941495.1670355408.1654571337-1133242073.1648131368
report.nih.govreport.nih.gov
  • 13report.nih.gov/funding/categorical-spending
cancer.govcancer.gov
  • 14cancer.gov/about-nci/budget
komen.orgkomen.org
  • 15komen.org/about-us/financials/
gminsights.comgminsights.com
  • 16gminsights.com/industry-analysis/breast-imaging-market
qualitynet.orgqualitynet.org
  • 17qualitynet.org/inpatient/measures/mipsimprovementactivity/demographics/measure-details?measureId=300E
acsjournals.onlinelibrary.wiley.comacsjournals.onlinelibrary.wiley.com
  • 18acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21876
  • 24acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21609
tandfonline.comtandfonline.com
  • 21tandfonline.com/doi/abs/10.1080/0742-9731.2020.1806105
academic.oup.comacademic.oup.com
  • 23academic.oup.com/jnci/article/113/12/dxab155/5852250
astro.orgastro.org
  • 25astro.org/Patient-Care-and-Research/Imaging-and-Diagnosis/Radiation-Therapy
data.hrsa.govdata.hrsa.gov
  • 27data.hrsa.gov/data/download?data=health-professional-shortage-area&download_format=csv
ahrq.govahrq.gov
  • 28ahrq.gov/research/findings/nhqrdr/nhqdr21/measures.html
sciencedirect.comsciencedirect.com
  • 30sciencedirect.com/science/article/pii/S1470204521000179
  • 33sciencedirect.com/science/article/pii/S0890623819305402
nejm.orgnejm.org
  • 32nejm.org/doi/full/10.1056/NEJMoa2024193
  • 38nejm.org/doi/full/10.1056/NEJMoa020845
  • 39nejm.org/doi/full/10.1056/NEJMoa010289
  • 40nejm.org/doi/full/10.1056/NEJMoa1913213
acr.orgacr.org
  • 34acr.org/-/media/ACR/Files/Survey/ACR-Radiology-Telehealth-Survey-2021.pdf
businesswire.combusinesswire.com
  • 35businesswire.com/news/home/20230322005433/en/Breast-Imaging-Market-Size-Worth-1-9-Billion-by-2022
asco.orgasco.org
  • 37asco.org/practice-patient-care/clinical-guidelines